A biotech with only two full-time employees now has millions of more dollars to spend in its work on an imaging molecule.
Based out of Minneapolis, MN, Vergent Bioscience announced Tuesday morning that investors handed the company $21.5 million via a Series B round. The last time the company got funding was in 2018, thanks to a Series A worth $8.7 million.
The biotech’s emphasis is in a molecule called VGT-309, a fluorescent imaging agent that would allow surgeons to more quickly find solid tumors in patients during surgery. The biotech had originally in-licensed the molecule from Stanford. CEO and president John Santini tells Endpoints News that initially, Vergent was looking at dyes for non-human use only, for R&D applications.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it’s free.
SIGN UP
LOG IN
